August 13, 2022 quadraScope Venture Fund’s presentation at the Ending Age-Related Diseases 2022 Conference
August 11, 2022 The 9th ARDD: Longevity Biotechnology Is Gaining Prominence and Credibility in the Pharmaceutical Industry
August 9, 2022 Portfolio: Immunis Announces FDA Clearance and Clinical Site for Phase 1/2a Clinical Trial Investigating Immune-Mediated Muscle Atrophy
July 19, 2022 Portfolio: Early Data from Mitochondrial Transplantation Study Indicates Longevity Potential
August 13, 2022 quadraScope Venture Fund’s presentation at the Ending Age-Related Diseases 2022 Conference
August 11, 2022 The 9th ARDD: Longevity Biotechnology Is Gaining Prominence and Credibility in the Pharmaceutical Industry
August 9, 2022 Portfolio: Immunis Announces FDA Clearance and Clinical Site for Phase 1/2a Clinical Trial Investigating Immune-Mediated Muscle Atrophy
July 19, 2022 Portfolio: Early Data from Mitochondrial Transplantation Study Indicates Longevity Potential